SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer

Table 4 Schedule of patient assessments through the study period

Schedule of Assessments							Notes
Visit Name	SCR	Simulation & treatment	2-week toxicity assessment^a	1st year follow up^b	Follow up years 2-5^c	Follow up year 6 and thereafter^d
Medical history	X
Concomitant medication review	X
Adverse events assessment			X	X	X	X
Physical examination	X			X	X	X
PSA	X			X	X	X	Staging PSA will be obtained within 1 month prior to enrollment
IPSS	X			X	X	X
EPIC	X			X	X	X
SHIM	X			X	X	X
Hydrogel spacer insertion	X
Staging PET CT/CT/Bone scan	X						optional
Prostate MRI	X				X		2-year MRI per physician recommendation
Prostate biopsy					X		Following the 2-year MRI– biopsy should be both targeted and systematic

a. For the first three patients. b. During the 1st -year, follow up will be performed at 1, 3, 6, 9, and 12 months. c. Every 6 months. d. Annually

ISSN: 1471-2407